FOOTHILL RANCH, Calif.– TAE Life Sciences (TLS), a biological-targeted radiation therapy company developing next-generation boron neutron capture therapy (BNCT), today announced the successful installation of its neutron beam system at Xiamen Humanity Hospital, the most advanced accelerator-based BNCT facility in Greater China, newly built in partnership with Neuboron Medical Group.
TLS’ Neutron Beam System enables a new treatment modality for patients diagnosed with the most aggressive and recurrent cancers such as gliomas, head and neck tumors, and melanomas, by delivering more precise, targeted radiation to cancer cells while sparing damage to surrounding healthy tissue. This technique holds promise in treating patients with cancer for whom other treatment options have been exhausted or are unavailable.
“The installation of our NBS at Xiamen Humanity Hospital represents a tremendous milestone in our mission to improve the lives of people diagnosed with invasive, recurrent and difficult to treat cancers,” said Bruce Bauer, Chief Executive Officer of TAE Life Sciences. “TAE Life Sciences is also developing comprehensive boron target drugs and a neutron technology product portfolio to enable BNCT as a new cancer treatment modality for patients globally. With the global pandemic challenging our installation plans along with restrictions in travel, this milestone is even more meaningful, and we want to thank our colleagues at Xiamen Humanity Hospital and our partner in China, Neuboron, for all of their efforts in helping to make this possible.”
Committed to developing a new generation of targeted radiotherapy for patients with cancer, TAE Life Sciences will present 5 oral presentations at the19th International Congress on Neutron Capture Therapy (ICNCT19) on BNCT, occurring virtually September 27 – October 1, 2021.
Accelerating New Hope in the Fight Against Cancer: Presentations at ICNCT19
- Product and Facility Design Optimization for an Accelerator BNCT Building Expansion Project in Pavia, Italy
- Development of new small molecule drugs for Boron Neutron Capture Therapy
- Target selection and development of antibody boron conjugates for boron neutron capture therapy of head and neck cancer
- Application of high fidelity radiation transport models to facility design, material selection, and shielding concepts for p-7Li accelerator based BNCT
- Architecture, Implementation and First Performance Results of a Neutron Beam System for Accelerator BNCT
In addition, TLS’s partner for China, Neuboron, will be presenting an update on the design and installation of the BNCT facility at Xiamen Humanity Hospital.
